Home › Funds › SAMLYN CAPITAL, LLC › ERAS
SAMLYN CAPITAL, LLC position in ERAS
ERASCA INC · Health Care
SAMLYN CAPITAL, LLC reported holding 2,256,986 shares of ERAS (ERASCA INC) in its Q2 2026 13F filing — a position valued at US$41.3M, representing 0.68% of its reported portfolio and ranking #45 among its reported holdings. SAMLYN CAPITAL, LLC first reported this position in Q2 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How SAMLYN CAPITAL, LLC's ERAS position evolved
SAMLYN CAPITAL, LLC first disclosed a stake in ERAS in Q2 2026 at 2,256,986 shares (US$41.3M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 2.26M | $41.35M | New |
About ERAS and 13F data
ERAS (ERASCA INC) is a Health Care company. 78 other funds we track also report a position in ERAS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$457.5M), RTW INVESTMENTS, LP (US$328.8M), Venrock Adviser, LLC (US$327.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ERAS
- Frazier Life Sciences Management, L.P. 24.98M sh · $457.55M · Q2 2026
- RTW INVESTMENTS, LP 17.95M sh · $328.78M · Q2 2026
- Venrock Adviser, LLC 17.89M sh · $327.78M · Q2 2026
- Logos Global Management LP 12.15M sh · $222.59M · Q2 2026
- Siren, L.L.C. 11.40M sh · $208.81M · Q2 2026
- Paradigm Biocapital Advisors LP 9.55M sh · $174.96M · Q2 2026
- ARCH Venture Management, LLC 7.09M sh · $129.92M · Q2 2026
- Cormorant Asset Management, LP 6.00M sh · $109.92M · Q2 2026
- Affinity Asset Advisors, LLC 5.25M sh · $96.18M · Q2 2026
- Vivo Capital, LLC 4.13M sh · $75.61M · Q2 2026
- a16z Capital Management, L.L.C. 2.86M sh · $52.44M · Q2 2026
- Soleus Capital Management, L.P. 2.70M sh · $49.46M · Q2 2026
More on SAMLYN CAPITAL, LLC
FAQ
How long has SAMLYN CAPITAL, LLC held ERAS?
SAMLYN CAPITAL, LLC has disclosed ERAS holdings in 1 of the last 1 reported quarters, going back to Q2 2026.
What is SAMLYN CAPITAL, LLC's current position in ERAS?
As of Q2 2026, SAMLYN CAPITAL, LLC holds 2.26M shares of ERAS (ERASCA INC), valued at $41.35M, representing 0.68% of its reported portfolio and ranking #45.
Has SAMLYN CAPITAL, LLC been buying or selling ERAS?
In the latest 13F filing (Q2 2026), SAMLYN CAPITAL, LLC newly opened its position in ERAS.
Which other funds hold ERAS?
Other major institutional holders of ERAS include Frazier Life Sciences Management, L.P., RTW INVESTMENTS, LP, Venrock Adviser, LLC, among 78 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.